Gotham Asset Management’s 9 Meters Biopharma NMTR Stock Holding History

Gotham Asset Management’s Portfolio NMTR Stock Details NMTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-42	Closed	-$1.22M	–	1080
2016 Q3	$1.22M	Buy	+42	New	+$23.2K	0.02%	570

Other funds holding NMTR

VKH

Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Gotham Asset Management's NMTR Position: Q4 2016 in Review

Gotham Asset Management sold out of 9 Meters Biopharma (NMTR) in Q4 2016, closing a stake of 42 shares — an estimated $1.22M sold.

Gotham Asset Management first reported a position in NMTR in Q3 2016 and held it in 1 quarter. The position peaked at $1.22M in Q3 2016. 7 funds tracked by Wall St. Rank hold NMTR as of Q4 2016.

Gotham Asset Management reported no remaining 9 Meters Biopharma position as of Q4 2016 after selling out during the quarter.
Gotham Asset Management sold 42 9 Meters Biopharma shares in Q4 2016, an estimated $1.22M.
Gotham Asset Management first reported a position in 9 Meters Biopharma in Q3 2016 and held it in 1 quarter.
Gotham Asset Management's 9 Meters Biopharma position peaked at $1.22M in Q3 2016.
7 funds tracked by Wall St. Rank held 9 Meters Biopharma as of Q4 2016.

Based on Gotham Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.